Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

Recruiting now

Conditions studied: Type 1 Diabetes

In brief

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Key facts

Study ID

NCT07676565

Run by

Indiana University

People needed

300

Starts

2026-03-24

Expected to finish

2028-04-01

Last updated by the study team

2026-06-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥18 years of age
• Clinical diagnosis of T1D
• GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
• Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
• Willing and able to provide informed consent

You may not qualify if…

• No exclusion criteria other than those not meeting inclusion criteria above

Where it is running

• Hoag Memorial Hospital — Newport Beach, California, United States (enrolling)
• Emory University — Atlanta, Georgia, United States (enrolling)
• Northwestern University — Chicago, Illinois, United States (enrolling)
• Maine Health Research Institute — Portland, Maine, United States (enrolling)
• Harvard Medical School — Boston, Massachusetts, United States (enrolling)
• Henry Ford Hospital — Detroit, Michigan, United States (enrolling)
• Mount Sinai — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.